Small Molecule Therapeutics for Schizophrenia by Sylvain CelanireSmall Molecule Therapeutics for Schizophrenia by Sylvain Celanire

Small Molecule Therapeutics for Schizophrenia

bySylvain CelanireEditorSonia Poli

Hardcover | October 30, 2014

Pricing and Purchase Info


Earn 830 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


The topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drug ability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine.
Title:Small Molecule Therapeutics for SchizophreniaFormat:HardcoverDimensions:323 pagesPublished:October 30, 2014Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3319115014

ISBN - 13:9783319115016

Look for similar items by category:


Table of Contents

Antipsychotics and the Dopamine-Serotonin Connection.- GLYT1 Inhibitors: From Hits to Clinical Candidates.- Metabotropic Glutamate Receptor 2 Activators.- Activation of the mGlu5 Receptor for the Treatment of Schizophrenia and Cognitive-Deficit-Associated Disorders.- Muscarinic Acetylcholine Receptor Activators.- Nicotinic Acetylcholine Receptor Modulators.- The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia.

Editorial Reviews

From the book reviews:

"The target audience . is primarily researchers in psychopharmacology involved in drug development. . Each chapter concludes with citations of the pertinent scientific literature. This book covering small molecular therapeutics for schizophrenia would be a useful review for researchers studying this area." (Michael Joel Schrift, Doody's Book Reviews, March, 2015)